ArticleJournal of cachexia, sarcopenia and muscle2020
Prognostic role of body composition parameters in gastric/gastroesophageal junction cancer patients from the EXPAND trial.
Article in Journal of cachexia, sarcopenia and muscle, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 2 syntheses or guidelines pooled it, 60 citations in OpenAlex.
- Computed Tomography-Defined Fat Composition as a Prognostic Marker in Gastric Adenocarcinoma: A Systematic Review and Meta-Analysis.Digestive diseases (Basel, Switzerland) · 2023Pooled it
- Adiposity and cancer survival: a systematic review and meta-analysis.Cancer causes & control : CCC · 2022Pooled it
- Beyond TNM staging: validation of a CT-derived nutritional-inflammatory composite model (RFMmSIS) for prognostication in resectable gastric cancer.BMC cancer · 2026Article
- Article
- The albumin-myosteatosis gauge predicts the response to neoadjuvant chemotherapy for locally advanced gastric cancer.Surgery today · 2025Article
- Change of bone mineral density as a prognostic marker in small cell lung cancer treated with immune checkpoint inhibitors: a multicenter retrospective study.Translational lung cancer research · 2025Article
- Impact of body composition parameters, age, and tumor staging on gastric cancer prognosis.European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) · 2025Article
- Clinical and body composition parameters as predictors of response to chemotherapy plus PD-1 inhibitor in gastric cancer.Frontiers in immunology · 2025Article
- ASO Author Reflections: Impact of 1-Year Changes in Skeletal Muscle Quality on Prognosis in Postoperative Patients with Early Gastric Cancer.Annals of surgical oncology · 2024Article
- Association Between Changes in Skeletal Muscle Quality and Prognosis in Postoperative Patients with Early Gastric Cancer.Annals of surgical oncology · 2024Article
- A Cross-Sectional Validation of Horos and CoreSlicer Software Programs for Body Composition Analysis in Abdominal Computed Tomography Scans in Colorectal Cancer Patients.Diagnostics (Basel, Switzerland) · 2024Article
- Predictive Value of a New Muscle Parameter in Patients with Resectable Gastric Cancer: A Pooled Analysis of Three Prospective Trials.Annals of surgical oncology · 2024Article
- Article
- CT-derived body composition: Differential association with disease, age and inflammation in a retrospective cohort study.PloS one · 2024Article
- Comparison Between the Clinical Effect of Percutaneous Kyphoplasty for Osteoporosis Vertebral Compression Fracture Patient with or Without Sarcopenia: A Retrospective Cohort Study.International journal of general medicine · 2023Article
- CT-determined low skeletal muscle mass predicts worse overall survival of gastric cancer in patients with cachexia.Cancer medicine · 2023Article
- Sarcopenia does not predict outcome in patients with CNS lymphoma undergoing systemic therapy.Oncology letters · 2022Article
- Preoperative mean platelet volume is a prognostic biomarker for survival in patients with gastric cancer: A cohort study.Medicine · 2022Article
- Body composition predictors of mortality in patients undergoing surgery for long bone metastases.Journal of surgical oncology · 2022Article
- Body composition predictors of mortality on computed tomography in patients with spinal metastases undergoing surgical treatment.The spine journal : official journal of the North American Spine Society · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBody fat and/or muscle composition influences prognosis in several cancer types. For advanced gastric and gastroesophageal junction cancer, we investigated which body composition parameters carry prognostic information beyond well-established clinical parameters using robust model selection strategy such that parameters identified can be expected to generalize and to be reproducible beyond our particular data set. Then we modelled how differences in these parameters translate into survival outcomes.
methodsFat and muscle parameters were measured on baseline computed tomography scans in 761 patients with advanced gastric or gastroesophageal junction cancer from the phase III EXPAND trial, undergoing first-line chemotherapy. Cox regression analysis for overall survival (OS) and progression-free survival (PFS) included body composition parameters and clinical prognostic factors. All continuous variables were entered linearly into the model as there was no evidence of non-linear prognostic impact. For transferability, the final model included only parameters that were picked by Bayesian information criterion model selection followed by bootstrap analysis to identify the most robust model.
resultsMuscle and fat parameters formed correlation clusters without relevant between-cluster correlation. Mean muscle attenuation (MA) clusters with the fat parameters. In multivariate analysis, MA was prognostic for OS (P < 0.0001) but not for PFS, while skeletal muscle index was prognostic for PFS (P = 0.02) but not for OS. Worse performance status Eastern Cooperative Oncology Group (ECOG 1/0), younger age (on a linear scale), and the number of metastatic sites were strong negative clinical prognostic factors for both OS and PFS. MA remained in the model for OS (P = 0.0001) following Bayesian information criterion model selection in contrast to skeletal muscle index that remained prognostic for PFS (P = 0.009). Applying stricter criteria for transferability, MA represented the only prognostic body composition parameter for OS, selected in >80% of bootstrap replicates. Finally, Cox model-derived survival curves indicated that large differences in MA translate into only moderate differences in expected OS in this cohort.
conclusionsAmong body composition parameters, only MA has robust prognostic impact for OS. Data suggest that treatment approaches targeting muscle quality are unlikely to prolong OS noticeably on their own in advanced gastric cancer patients, indicating that multimodal approaches should be pursued in the future.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.